secwatch.observer — SEC 8-K summary
======================================

Issuer:     Forte Biosciences, Inc. (FBRX)
CIK:        0001419041
Form:       8-K
Filed at:   2025-11-14T23:59:59+00:00
Accession:  0001193125-25-281807
Event type: earnings
Sentiment:  neutral
Materiality: 0.60
Item codes: 2.02, 9.01
LLM model:  deepseek-v4-flash:cloud@v2

Forte Biosciences Q3 net loss $17.7M; cash $93.4M; three FB102 readouts in 2026
-------------------------------------------------------------------------------

- Net loss of $17.7M ($0.99 per share) for Q3 2025 vs $8.4M loss in Q3 2024.
- R&D expenses $15.2M, up from $5.9M YoY, driven by FB102 clinical programs.
- Cash and equivalents $93.4M as of Sept 30, 2025, up from $22.2M at year-end 2024.
- FB102 phase 2 celiac disease enrolling US sites; topline data expected in 2026.
- Phase 1b vitiligo data expected 1H26; alopecia areata study enrolling, data in 2026.

Source:
  EDGAR index:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525281807/0001193125-25-281807-index.htm
  Primary doc:    https://www.sec.gov/Archives/edgar/data/1419041/000119312525281807/d77724d8k.htm
  HTML page:      https://secwatch.observer/filing/0001193125-25-281807

License: Source filings: public domain (SEC EDGAR). Summaries (headline + bullets): CC-BY-4.0; attribute https://secwatch.observer